•   1997: Jinhua Lixin Pharmaceutical and Chemical Co., Ltd. was founded

•   2002: Establishment of Zhejiang Nieskang Pharmaceutical Co., Ltd. (Dongxi Factory)

•   2002: Acquisition of Jiangxi Liming Pharmaceutical Factory and Establishment of Jiangxi Lixin Pharmaceutical Co., Ltd.

•   2002: Establishment of Zhejiang Neiskang Pharmaceutical Co., Ltd. (Linjiang Factory)

•  December 2009: Successful mergers and acquisitions by Bioveda and NEA

•  March 2010: Clarithromycin was certified by PMDA in Japan

•  April 2011: Ciprofibrate through COFEPRIS, Mexico

•  May 2011: Glimepiride was certified by the Provincial Center for Pharmaceutical and Economic Development in Ciprofibrate.

•  April 2012: Azithromycin, Clarithromycin, Roxithromycin and Benzylhydrazine Hydrochloride passed the GMP postponement certification of Jinhua Pharmaceutical Administration.

•  June 2013: Azithromycin was certified by PMDA in Japan

•  October 2013: Fenofibrate passed GMP postponement certification of Jinhua Drug Administration

•  December 2014: Azithromycin was certified by Brazilian ANVISA

•  July 2015: Merger and reorganization by Jinhua Kangbei Biopharmaceutical Co., Ltd.

•  March 2016: Clarithromycin and Roxithromycin are certified by SFDA on-site GMP

•  July 2016: Clarithromycin was certified by EDQM

•  September 2016: Benzylhydrazine hydrochloride and azithromycin passed SFDA GMP certification

•  August 2018: Ciprofibrate, glimepiride passed the on-site certification of the Provincial Center for Pharmaceutical and Economic Development

•  April 2019:Bensihydrazine hydrochloride has passed MFDS site certification in Korea

•  September 2019:Clarithromycin passed the Japanese PMDA site certification